India, Nov. 17 -- CytomX Therapeutics, Inc. (CTMX) announced the achievement of a preclinical milestone in its cancer research collaboration with Regeneron Pharmaceuticals, triggering a $5 million milestone payment to CytomX.
The milestone relates to one of the lead programs being developed under the companies' partnership, which combines CytomX's PROBODY masking technology with Regeneron's Veloci-Bi bispecific antibody platform.
The collaboration focuses on developing conditionally activated bispecific antibodies designed to remain inactive in systemic circulation until activated by protease highly enriched in the tumor environment. The approach aims to improve the precision of cancer treatments and potentially reduce unwanted side effec...